NervGen Pharma Corp (NGEN) - Cash Flow Conversion Efficiency

Latest as of September 2025: 1.808x

Based on the latest financial reports, NervGen Pharma Corp (NGEN) has a cash flow conversion efficiency ratio of 1.808x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-5.32 Million ≈ $-3.85 Million USD) by net assets (CA$-2.94 Million ≈ $-2.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NervGen Pharma Corp balance sheet quality to measure how much of total assets are equity-financed.

NervGen Pharma Corp - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how NervGen Pharma Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore NGEN long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

NervGen Pharma Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NervGen Pharma Corp ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Polaris Media OL:POL	0.072x
Eimskipafélag Íslands hf IC:EIM	0.017x
Sprott Focus Trust NASDAQ:FUND	N/A
LINAS AGRO GROUP EO 029 F:YG4	-0.034x
STEICO SE XETRA:ST5	0.150x
China Tian Lun Gas Holdings Limited F:TLJ	0.027x
Relais Group Oyj HE:RELAIS	-0.002x
Kogan.com Ltd AU:KGN	-0.163x

Annual Cash Flow Conversion Efficiency for NervGen Pharma Corp (2017–2024)

The table below shows the annual cash flow conversion efficiency of NervGen Pharma Corp from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see NervGen Pharma Corp (NGEN) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CA$2.58 Million ≈ $1.86 Million	CA$-16.84 Million ≈ $-12.18 Million	-6.536x	-216.26%
2023-12-31	CA$-2.01 Million ≈ $-1.45 Million	CA$-11.30 Million ≈ $-8.17 Million	5.622x	+525.55%
2022-12-31	CA$13.46 Million ≈ $9.74 Million	CA$-17.78 Million ≈ $-12.86 Million	-1.321x	-168.70%
2021-12-31	CA$16.82 Million ≈ $12.17 Million	CA$-8.27 Million ≈ $-5.98 Million	-0.492x	+53.85%
2020-12-31	CA$5.92 Million ≈ $4.28 Million	CA$-6.31 Million ≈ $-4.56 Million	-1.065x	+23.12%
2019-12-31	CA$5.84 Million ≈ $4.23 Million	CA$-8.09 Million ≈ $-5.86 Million	-1.386x	-234.95%
2018-12-31	CA$2.51 Million ≈ $1.82 Million	CA$-1.04 Million ≈ $-752.38K	-0.414x	-100.47%
2017-12-31	CA$-11.81K ≈ $-8.55K	CA$-1.04 Million ≈ $-752.38K	88.045x	--

About NervGen Pharma Corp

V:NGEN Canada Biotechnology

Market Cap

$295.10 Million

CA$407.94 Million CAD

Market Cap Rank

#14851 Global

#443 in Canada

Share Price

CA$5.15

Change (1 day)

+0.00%

52-Week Range

CA$2.79 - CA$8.08

All Time High

CA$8.08